Expert Working Group Finds Insufficient Evidence Linking Ibuprofen and COVID-19 Susceptibility
The Commission of Human Medicines Expert Working Group has concluded that there is insufficient evidence to link ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), with susceptibility for contracting COVID-19 or worsening symptoms.
The Commission of Human Medicines (CHM) Expert Working Group has concluded that there is insufficient evidence to link ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), with susceptibility for contracting COVID-19 or worsening symptoms.
CHM’s Expert Working Group’s findings were published in an April 14, 2020 press release issued by CHM and the Medicines and Healthcare products Regulatory Agency of the United Kingdom. As a result of the findings, the advice is for patients to use paracetamol or ibuprofen when self-medicating symptoms of COVID-19 but that should further questions arise or if symptoms start to worsen they should follow the advice of the National Health Service.
The government response comes after there was some confusion over the potential link between NSAIDs and the potential of worsening COVID-19 symptoms, reports of which had been circulated widely on social media platforms. The European Medicines Agency issued advice about NSAIDs and COVID-19 in March and stated that the issue will be closely monitored.
Source: Gov.uk
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
